Covaxin Phase 2-3 Clinical Trials for Age Group 2-18 Begins on June
Bharat Biotech s Covaxin will begin Phase 2 and 3 clinical trials in the age group of 2 to 18 years in June, according to sources at the Hyderabad-based vaccine manufacturer.
| 24 May 2021 1:11 PM GMT
Bharat Biotech s Covaxin will begin Phase 2 and 3 clinical trials in the age group of 2 to 18 years in June, according to sources at the Hyderabad-based vaccine manufacturer.
Covaxin is being used on adults in India s ongoing Covid-19 vaccination drive, which was created by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Bharat Biotech was granted permission to conduct a Phase 2/3 clinical trial of Covaxin in children aged 2 to 18 years old earlier this month.
Covaxin Phase 2-3 clinical trials for 2-18 age group to begin in June, youngest participant 2-year-old
The Phase 2-3 clinical trials of Covaxin, which has been approved by the DCGI for the age group of 2 to 18 years, will begin in June, as per reliable sources.
advertisement
UPDATED: May 24, 2021 13:49 IST
In the trials, Covaxin will be given by intramuscular route in two doses at day 0 and day 28. (PTI photo for representation)
The Phase 2 and 3 clinical trials of Bharat Biotech’s Covaxin in the age group of 2 to 18 years will begin in June, sources in the Hyderabad-based vaccine maker have said.
Sources at Bharat Biotech told India Today that the Phase 2/3 trails for children will begin in June. Dosing will begin in June and end by mid-July. The youngest child recruited for the clinical study is a two-year-old, Bharat Biotech sources added.
Covaxin production ramped to 1 billion doses per year: Bharat Biotech
The additional doses would be produced at its wholly-owned subsidiary Chiron Behring Vaccines situated in Ankleshwar, Gujarat and the product availability will commence from Q4 2021
BusinessToday.In | May 20, 2021 | Updated 22:35 IST
Homegrown biotechnology company Bharat Biotech, on Thursday, announced expansion of Covaxin production capacity by 200 million doses, taking its total capacity to around 1 billion doses per annum.
Bharat Biotech, in a statement, said the company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety.
Do Kids Need Covid Vaccines, What Are The Side Effects And Precautions, Know From Expert
Outlook got in touch with Dr. Prabhat Maheshwari, Chief- Neonatal & Paediatric Critical Care, Artemis Hospitals Gurgaon to answer all your questions:
Dr. Prabhat Maheshwari 17 May 2021, Last Updated at 7:30 am File photo Dr. Prabhat Maheshwari 2021-05-17T07:25:02+05:30 Do Kids Need Covid Vaccines, What Are The Side Effects And Precautions, Know From Expert outlookindia.com 2021-05-17T07:30:29+05:30
Also read
With Bharat Biotech’s inactivated virus-based Covid-19 vaccine Covaxin now set for phase 2 and 3 clinical trials on children in the 2-12 years age group, the stage is set for a pediatric range to hit the market. Experts believe this is a critical step to ensure a break in transmission.
Covid Explained: How Phase 2 And 3 Trials For Covaxin On Kids Will Be Conducted?
Covid explained: The trial will be conducted on 525 healthy volunteers at different sites across the country. These sites are expected to include AIIMS, Delhi and AIIMS, Patna as well as the Meditrina Institute of Medical Sciences in Nagpur.
Outlook Web Bureau 14 May 2021, Last Updated at 8:02 am File photo Outlook Web Bureau 2021-05-14T07:58:29+05:30 Covid Explained: How Phase 2 And 3 Trials For Covaxin On Kids Will Be Conducted? outlookindia.com 2021-05-14T08:02:02+05:30
Also read
What is Covaxin?
Covaxin is one of the two Covid-19 vaccines used in India’s mass vaccination drive against the virus. It has been developed by Hyderabad-headquartered vaccine-maker Bharat Biotech in collaboration with the government’s Indian Council of Medical Research (ICMR).